Detection of phospholipidosis induction: A cell-based assay in high-throughput and high-content format

Journal of Biomolecular Screening

Volumn 19, Issue 1, 2014, Pages 66-76

  Shahane, Sampada A ^a   Huang, Ruili ^a   Gerhold, David ^a   Baxa, Ulrich ^b   Austin, Christopher P ^a   Xia, Menghang ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b SAIC FREDERICK INC   (United States)

Author keywords

LipidTOX; phospholipidosis; qHTS

Indexed keywords

1 (2 METHOXYPHENYL) 4 (4 PHTHALIMIDOBUTYL)PIPERAZINE; AMANTADINE; AMIODARONE; AMITRIPTYLINE; CHLOROQUINE; CHLORPROMAZINE; CITALOPRAM; CLOMIPRAMINE; CLOZAPINE; DESIPRAMINE; DOXEPIN; EBASTINE; FLUOXETINE; FLUPENTIXOL; HALOPERIDOL; IMIPRAMINE; KETOCONAZOLE; LABETALOL; LORATADINE; MAPROTILINE; MEMANTINE; MEPACRINE; N [4 METHOXY 3 (4 METHYL 1 PIPERAZINYL)PHENYL] 2' METHYL 4' (5 METHYL 1,2,4 OXADIAZOL 3 YL)[1,1' BIPHENYL] 4 CARBOXAMIDE; PAROXETINE; PENTAMIDINE; PROMAZINE; PROPRANOLOL; QUINIDINE; TAMOXIFEN; UNINDEXED DRUG;

ARTICLE; CELL ASSAY; CELL STRAIN HEPG2; CELL VIABILITY; CYTOPLASM; DRUG CYTOTOXICITY; DRUG INDUCED DISEASE; ELECTRON MICROSCOPY; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; IC 50; LIPIDOSIS; PRIORITY JOURNAL; PROTEIN DETERMINATION; QUANTITATIVE ANALYSIS;

LIPIDTOX; PHOSPHOLIPIDOSIS; QHTS;

HEP G2 CELLS; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; INTRACELLULAR SPACE; LIPIDOSES; MICROSCOPY, ELECTRON, TRANSMISSION; PHOSPHOLIPIDS; REPRODUCIBILITY OF RESULTS;

EID: 84890855178     PISSN: 10870571     EISSN: 1552454X     Source Type: Journal    
DOI: 10.1177/1087057113502851     Document Type: Article

References (35)

1. Reasor M. J.. A Review of the Biology and Toxicologic Implications of the Induction of Lysosomal Lamellar Bodies by Drugs. Toxicol. Appl. Pharmacol. 1989 ; 97: 47-56
2. Reasor M. J., Kacew S.. An Evaluation of Possible Mechanisms Underlying Amiodarone-Induced Pulmonary Toxicity. Proc. Soc. Exp. Biol. Med. 1996 ; 212: 297-304
3. Ruben Z., Dodd D. C., Rorig K. J., et al. Disobutamide: A Model Agent for Investigating Intracellular Drug Storage. Toxicol. Appl. Pharmacol. 1989 ; 97: 57-71
4. Oikawa H., Maesawa C., Sato R., et al. Liver Cirrhosis Induced by Long-Term Administration of a Daily Low Dose of Amiodarone: A Case Report. World J. Gastroenterol. 2005 ; 11: 5394-5397
5. Kaloyanides G. J., Pastoriza-Munoz E.. Aminoglycoside Nephrotoxicity. Kidney Int. 1980 ; 18: 571-582
6. Reasor M. J., Hastings K. L., Ulrich R. G.. Drug-Induced Phospholipidosis: Issues and Future Directions. Expert Opin. Drug Saf. 2006 ; 5: 567-583
7. Shaikh N. A., Downar E., Butany J.. Amiodarone - an Inhibitor of Phospholipase Activity: A Comparative Study of the Inhibitory Effects of Amiodarone, Chloroquine and Chlorpromazine. Mol. Cell Biochem. 1987 ; 76: 163-172
8. Joshi U. M., Rao P., Kodavanti S., et al. Fluorescence Studies on Binding of Amphiphilic Drugs to Isolated Lamellar Bodies: Relevance to Phospholipidosis. Biochim. Biophys. Acta. 1989 ; 1004: 309-320
9. Horn J. W., Jensen C. B., White S. L., et al. In Vitro and In Vivo Ultrastructural Changes Induced by Macrolide Antibiotic LY281389. Fundam. Appl. Toxicol. 1996 ; 32: 205-216
10. Laurent G., Kishore B. K., Tulkens P. M. Aminoglycoside-Induced Renal Phospholipidosis and Nephrotoxicity. Biochem. Pharmacol. 1990 ; 40: 2383-2392
11. Reasor M. J., Ogle C. L., Kacew S.. Amiodarone-Induced Pulmonary Toxicity in Rats: Biochemical and Pharmacological Characteristics. Toxicol. Appl. Pharmacol. 1989 ; 97: 124-133
12. Berridge B. R., Chatman L. A., Odin M., et al. Phospholipidosis in Nonclinical Toxicity Studies. Toxicol. Pathol. 2007 ; 35: 325
13. Gum R. J., Hickman D., Fagerland J. A., et al. Analysis of Two Matrix Metalloproteinase Inhibitors and Their Metabolites for Induction of Phospholipidosis in Rat and Human Hepatocytes(1). Biochem. Pharmacol. 2001 ; 62: 1661-1673
14. Morelli J. K., Buehrle M., Pognan F., et al. Validation of an In Vitro Screen for Phospholipidosis Using a High-Content Biology Platform. Cell Biol. Toxicol. 2006 ; 22: 15-27
15. Kasahara T., Tomita K., Murano H., et al. Establishment of an In Vitro High-Throughput Screening Assay for Detecting Phospholipidosis-Inducing Potential. Toxicol. Sci. 2006 ; 90: 133-141
16. Casartelli A., Bonato M., Cristofori P., et al. A Cell-Based Approach for the Early Assessment of the Phospholipidogenic Potential in Pharmaceutical Research and Drug Development. Cell Biol. Toxicol. 2003 ; 19: 161-176
17. Nioi P., Perry B. K., Wang E. J., et al. In Vitro Detection of Drug-Induced Phospholipidosis Using Gene Expression and Fluorescent Phospholipid Based Methodologies. Toxicol. Sci. 2007 ; 99: 162-173
18. Sakamuru S., Li X., Attene-Ramos M. S., et al. Application of a Homogenous Membrane Potential Assay to Assess Mitochondrial Function. Physiol. Genomics. 2012 ; 44: 495-503
19. Bhandari N., Figueroa D. J., Lawrence J. W., et al. Phospholipidosis Assay in HepG2 Cells and Rat or Rhesus Hepatocytes Using Phospholipid Probe NBD-PE. Assay Drug Dev. Technol. 2008 ; 6: 407-419
20. Southall N. T., Jadhav A., Huang R., et al Handbook of Drug Screening. Seethala R. Zhang L., ed. New York: Taylor and Francis ; 2009: 442-463.
21. Muehlbacher M., Tripal P., Roas F., et al. Identification of Drugs Inducing Phospholipidosis by Novel In Vitro Data. ChemMedChem. in press ;:
22. Frisch W., Lullmann-Rauch R. Effects of Several Lipidosis-Including Drugs upon the Area Postrema and Adjacent Medullary Nuclei of Adult Rats, I: Alterations in Perikarya and Dendrites. Acta Neuropathol. 1980 ; 52: 179-187
23. Kruhlak N. L., Choi S. S., Contrera J. F., et al. Development of a Phospholipidosis Database and Predictive Quantitative Structure-Activity Relationship (QSAR) Models. Toxicol. Mech. Methods. 2008 ; 18: 217-227
24. Kacew S.. Gentamicin or Chlorphentermine Induction of Phospholipidosis in the Developing Organism: Role of Tissue and Species in Manifestation of Toxicity. J. Pharmacol. Exp. Ther. 1985 ; 232: 239-243
25. Sawada H., Takami K., Asahi S. A Toxicogenomic Approach to Drug-Induced Phospholipidosis: Analysis of Its Induction Mechanism and Establishment of a Novel In Vitro Screening System. Toxicol. Sci. 2005 ; 83: 282-292
26. Kodavanti U. P., Mehendale H. M.. Cationic Amphiphilic Drugs and Phospholipid Storage Disorder. Pharmacol. Rev. 1990 ; 42: 327-354
27. Van Cauwenberge P., De Belder T., Sys L. A Review of the Second-Generation Antihistamine Ebastine for the Treatment of Allergic Disorders. Expert Opin. Pharmacother. 2004 ; 5: 1807-1813
28. Yap Y. G., Camm A. J.. Drug Induced QT Prolongation and Torsades de Pointes. Heart. 2003 ; 89: 1363-1372
29. Ko C. M., Ducic I., Fan J., et al. Suppression of Mammalian K+ Channel Family by Ebastine. J Pharmacol. Exp. Ther. 1997 ; 281: 233-244
30. Skingle M., Beattie D. T., Scopes D. I., et al. GR127935: A Potent and Selective 5-HT1D Receptor Antagonist. Behav. Brain Res. 1996 ; 73: 157-161
31. Thielen R. J., Fangon N. B., Frazer A.. 4-(2′-Methoxyphenyl)-1- [2′-[N-(2′′-Pyridinyl)-p-iodobenzamido]ethyl] Piperazine and 4-(2′-Methoxyphenyl)-1-[2′-[N-(2′′-Pyridinyl)-p- Fluorobenzamido]ethyl]piperazine, Two New Antagonists at Pre- and Postsynaptic Serotonin-1A Receptors. J. Pharmacol. Exp. Ther. 1996 ; 277: 661-670
32. Sharp T., Hjorth S. Application of Brain Microdialysis to Study the Pharmacology of the 5-HT1A Autoreceptor. J. Neurosci. Methods. 1990 ; 34: 83-90
33. Taylor D.. Psychopharmacology and Adverse Effects of Antipsychotic Long-Acting Injections: A Review. Br. J. Psychiatry Suppl. 2009 ; 52: S13 - S19
34. Squires R. F., Saederup E.. Clozapine and Several Other Antipsychotic/Antidepressant Drugs Preferentially Block the Same 'Core' Fraction of GABA(A) Receptors. Neurochem. Res. 1998 ; 23: 1283-1290
35. Cerep Phospholipidosis Application Note. http://www.cerep.fr/cerep/users/ pages/downloads/Documents/Marketing/Pharmacology%20&%20ADME/ Application%20notes/2011%20Phospholipidosis.pdf